Key facts: GSK's asthma drug Exdensur approved; share buyback completed
I'm PortAI, I can summarize articles.
GSK's asthma drug Exdensur (depemokimab) has gained approvals from the UK MHRA and U.S. FDA as an add-on treatment for severe asthma, with a twice-yearly dosing schedule.123On December 16, 2025, GSK plc bought back 13.6 million shares, raising its treasury shares to 239.1 million. Total shares issued, excluding treasury, is 4.1 billion.4
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments